Cecilia Peralta1, Federico Biafore2, Tamara Soto Depetris3, Maria Bastianello4. 1. Department of Neurology, CEMIC University Hospital, Elias Galván 4102, C1431FWO, Buenos Aires, Argentina. ceciliaperalta@yahoo.com.ar. 2. Department of Biostatistics, School of Science and Technology, National University of San Martín, Campus Miguelete, 25 de Mayo y Francia, Buenos Aires, Argentina. 3. Department of Neurology, CEMIC University Hospital, Elias Galván 4102, C1431FWO, Buenos Aires, Argentina. 4. Department of Molecular and Metabolic Imaging, CEMIC University Hospital, Elias Galván, 4102, Buenos Aires, Argentina.
Abstract
PURPOSE OF REVIEW: The molecular imaging field has been very instrumental in identifying the multiple network interactions that compose the human brain. The cerebral glucose metabolism is associated with neural function. 18F-fluoro-deoxyglucose-PET (FDG-PET) studies reflect brain metabolism in a pattern-specific manner. This article reviews FDG-PET studies in Parkinson's disease (PD), atypical parkinsonism (AP), Huntington's disease (HD), and dystonia. RECENT FINDINGS: The metabolic pattern of PD, disease progression, non-motor symptoms such as fatigue, depression, apathy, impulse control disorders, and cognitive impairment, and the risk of progression to dementia have been identified with FDG-PET studies. In prodromal PD, the REM sleep behavior disorder-related covariance pattern has been described. In AP, FDG-PET studies have demonstrated to be superior to D2/D3 SPECT in differentiating PD from AP. The metabolic patterns of HD and dystonia have also been described. FDG-PET studies are an excellent tool to identify patterns of brain metabolism.
PURPOSE OF REVIEW: The molecular imaging field has been very instrumental in identifying the multiple network interactions that compose the human brain. The cerebral glucose metabolism is associated with neural function. 18F-fluoro-deoxyglucose-PET (FDG-PET) studies reflect brain metabolism in a pattern-specific manner. This article reviews FDG-PET studies in Parkinson's disease (PD), atypical parkinsonism (AP), Huntington's disease (HD), and dystonia. RECENT FINDINGS: The metabolic pattern of PD, disease progression, non-motor symptoms such as fatigue, depression, apathy, impulse control disorders, and cognitive impairment, and the risk of progression to dementia have been identified with FDG-PET studies. In prodromal PD, the REM sleep behavior disorder-related covariance pattern has been described. In AP, FDG-PET studies have demonstrated to be superior to D2/D3 SPECT in differentiating PD from AP. The metabolic patterns of HD and dystonia have also been described. FDG-PET studies are an excellent tool to identify patterns of brain metabolism.
Authors: Thomas Eckert; Anna Barnes; Vijay Dhawan; Steve Frucht; Mark F Gordon; Andrew S Feigin; D Eidelberg Journal: Neuroimage Date: 2005-04-26 Impact factor: 6.556
Authors: Andrea Ciarmiello; Milena Cannella; Secondo Lastoria; Maria Simonelli; Luigi Frati; David C Rubinsztein; Ferdinando Squitieri Journal: J Nucl Med Date: 2006-02 Impact factor: 10.057
Authors: P C Su; Y Ma; M Fukuda; M J Mentis; H M Tseng; R F Yen; H M Liu; J R Moeller; D Eidelberg Journal: Ann Neurol Date: 2001-10 Impact factor: 10.422
Authors: Maja Trost; Maren Carbon; Christine Edwards; Yilong Ma; Deborah Raymond; Marc J Mentis; James R Moeller; Susan B Bressman; David Eidelberg Journal: Ann Neurol Date: 2002-12 Impact factor: 10.422
Authors: Annemarie M M Vlaar; Marinus J P G van Kroonenburgh; Alfons G H Kessels; Wim E J Weber Journal: BMC Neurol Date: 2007-09-01 Impact factor: 2.474
Authors: Eric Guedj; Andrea Varrone; Ronald Boellaard; Nathalie L Albert; Henryk Barthel; Bart van Berckel; Matthias Brendel; Diego Cecchin; Ozgul Ekmekcioglu; Valentina Garibotto; Adriaan A Lammertsma; Ian Law; Iván Peñuelas; Franck Semah; Tatjana Traub-Weidinger; Elsmarieke van de Giessen; Donatienne Van Weehaeghe; Silvia Morbelli Journal: Eur J Nucl Med Mol Imaging Date: 2021-12-09 Impact factor: 10.057